Toboroz
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT07388524· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Vamsi K. Vasireddy (principal investigator)
Toboroz
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
NCT07504588· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Kendrith M. Rowland (principal investigator)
Toboroz
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
NCT07220187· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· 3. fázis· NRG Oncology· Forrás
Contact: Tanmay Sahai (principal investigator)
Toboroz
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Maria T. Grosse-Perdekamp (principal investigator)
Toboroz
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Prem Sobti (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Family Communications After Genetic Testing
NCT07143487· Alliance for Clinical Trials in Oncology· Forrás
Contact: Prem Sobti (principal investigator)
Toboroz
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· 3. fázis· NRG Oncology· Forrás
Contact: Prem Sobti (principal investigator)
Toboroz
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Pratima Chalasani (principal investigator)
Toboroz
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT06931340· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Kendrith M. Rowland (principal investigator)
Toboroz
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Kendrith M. Rowland (principal investigator)
Toboroz
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Prem Sobti (principal investigator)
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· 3. fázis· NRG Oncology· Forrás
Contact: Sinisa Stanic (principal investigator)
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: Daniel H. Barnett (principal investigator)
Toboroz
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06532279· 2. fázis· NRG Oncology· Forrás
Contact: Sinisa Stanic (principal investigator)
Toboroz
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Vamsi K. Vasireddy (principal investigator)
Toboroz
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
NCT06992427· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Daniel H. Barnett (principal investigator)
Toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Daniel H. Barnett (principal investigator)
Toboroz
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Tanmay Sahai (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Pratima Chalasani (principal investigator)
Toboroz
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Forrás
Contact: Kendrith M Rowland (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Tanmay Sahai (principal investigator)
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Fut, nem toboroz
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Tanmay Sahai (principal investigator)
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Tanmay Sahai (principal investigator)
Toboroz
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Priyank P. Patel (principal investigator)
Toboroz
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Prem Sobti (principal investigator)
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Suparna Mantha (principal investigator)
Toboroz
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Vamsi K. Vasireddy (principal investigator)
Fut, nem toboroz
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Priyank P. Patel (principal investigator)
Fut, nem toboroz
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Sinisa Stanic (principal investigator)
Toboroz
Vitamin D for Prostate Endocrine Therapy
NCT05838716· 3. fázis· University of Rochester· Forrás
Contact: Vamsi K. Vasireddy (principal investigator)
Showing 50 of 220.